Blog
From Insight to Impact: A KOL Network Builds Prescribing Readiness, Early Adoption
Erin Conlan, Growth & Strategy Lead, Health Communications Group, IQVIA
Danielle Kennedy, Solution Sales Specialist, Content & Engagement, IQVIA
Mary Beth Workman, Sr. Director, Strategic Solutions, Content & Engagement, IQVIA
Melissa Marth, VP & GM, Content & Engagement, IQVIA
Nov 18, 2026

Recent data have indicated that the rate of healthcare provider (HCP) adoption of a given therapy increases by 25% when a key opinion leader (KOL) adopts that same therapy1. Additionally, KOLs influence research, patient advocacy and health policy – all of which require strategic, integrated partnerships rather than transactional interactions2. Thus, KOLs play a critical role in interpreting evidence, shaping clinical dialogue and helping peers and patients understand emerging science. Building an effective KOL strategy and network require a well-crafted narrative focusing on:

  • Credibility: Is the message evidence-based and scientifically sound?
  • Relevance: Does it address issues pertinent to target the physician’s practice, patient population, care pathway, evidence expectations and access realities?
  • Timing: Are you delivering information when it is most useful?
  • Specificity: Does the message answer a clear scientific or clinical question?
  • Behavioral awareness: Does it reflect how clinicians and peer-to-peer networks evaluate and apply new information?
  • Omnichannel readiness: Can the message be delivered consistently across multiple engagement channels?
  • Measurement: Do you have clear indicators that show whether understanding and readiness are improving?

These dimensions align with evidence that physician decisions are shaped by social networks, heuristics, workflow constraints and information context3.

Build readiness during prelaunch

The 12- to 24-month prelaunch period is your opportunity to establish a strong foundation.

During this stage, focus on understanding the disease landscape and the questions KOLs are most likely to ask. This includes exploring unmet need, current standards of care, diagnostic challenges, emerging evidence, knowledge gaps and treatment gaps.

Concentrate on generating data-driven insights that can inform future scientific discussions. Advisory boards, disease-state conversations and evidence-generation activities can help identify areas where clinicians need greater clarity.

The output should be a clear understanding of the ingrained beliefs that may prevent adoption or acceptance once launch approaches.

Prepare for launch

As you enter the six- to 12-month prelaunch period, the focus shifts from insight generation to readiness.

KOLs often want to understand the clinical significance of the data, the potential place in therapy, unresolved evidence questions and the broader implications for patient care. The goal is to ensure that your scientific narrative is coherent, relevant and aligned with stakeholder needs.

A useful framework is to connect every communication:

From Insight to Impact: A KOL Network Builds Prescribing Readiness, Early Adoption 

Start with the belief you want to change. Identify the barrier preventing understanding or action. Develop a message that addresses that belief shift. Determine the right moment and format for delivery. Finally, establish measurable signals that indicate whether readiness is improving.

Adapt approach for different launch environments

In large, competitive therapeutic areas, KOLs often evaluate multiple treatment options and evolving standards of care. Success depends on helping these stakeholders clearly understand where a new therapy fits within an increasingly crowded evidence landscape.

Rare disease launches present a different challenge. In many cases, awareness, diagnosis, and referral patterns remain significant barriers to treatment. Patient populations may be small, clinical experience may be limited, and evidence generation may be more complex than in broader therapeutic categories.

As a result, rare disease messaging often requires greater emphasis on disease education, patient identification, natural history and the practical realities of managing a small patient population. Scientific clarity can be just as important as product differentiation.

Message effectiveness, not volume, determines launch readiness and begins long before launch day. It begins when every message serves a purpose and every interaction helps build understanding.

As a brand leader, launching a new therapy balances numerous, often competing priorities, and IQVIA Health Communications Group is here to serve as your strategic communications partner. IHCG represents a family of specialized communication agencies, dedicated to turning complex, rich data into validated insights and belief-changing, behavior-aware messaging that builds and motivates your KOL network.

This blog is the fourth in a series exploring how to build launch readiness across four critical audiences: HCPs, KOLs, payers and patients, and how an expert communications partner can make launch communications seamless.

Ultimately, launch success is measured by how effectively you prepare stakeholders to understand the unmet need, recognize the value of your therapy and make confident decisions when launch day arrives.

Sources:

  1. IQVIA Modern Launch in the US: https://www.iqvia.com/locations/united-states/library/publications/modern-launch-in-the-us
  2. Measure, Master, Move: An Ecosystem Approach to Engaging KOLs Beyond the Clinic - Medical Affairs Professional Society
  3. Can peer effects explain prescribing appropriateness? a social network analysis Can peer effects explain prescribing appropriateness? a social network analysis - PMC

Effective payer messaging: deliver value before coverage begins

Payers exert unprecedented control over access to new therapies. Developing payer messaging should help them evaluate value, manage uncertainty and risk and prepare for coverage decisions, rather than simply increase awareness and more content than needed.

Related solutions